|
|
|
International Clinical Trials
|
In the history of medical research, the concept of patient centricity is a relatively new one. Until a few years ago, the primary focus of most clinical trials was developing drugs for commercial application. Patients were important and necessary to this process, but only because they represented the human connection to data the development team needed to move a drug candidate or treatment option through the regulatory approval process.
Unsurprisingly, patients who did become involved in clinical trials often felt disrespected and unimportant. As the industry accepted that patients’ generally low levels of satisfaction translated into compliance issues and high dropout rates, as well as broadly negative perceptions of clinical research that contribute to the limited participation rates of today, interest began to rise in assessing and addressing patient concerns.
By the mid-2000s, terms such as ‘patient centricity’ and ‘patientcentric trials’ had begun to find their way into publications and presentations. Although precise definitions vary, the underlying concept from the beginning is that providing patients with more information and greater integration into the trial process will lead to greater patient satisfaction and improved outcomes for sponsors, research centres, and patients. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Aptus Clinical enters into a global partnership agreement with Artelo Biosciences
We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >> |
|
 |
White Papers |
 |
|
Choosing the Right CMO for HPAPI Manufacturing
AMRI
Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >> |
|
 |
Industry Events |
 |
SCOPE Europe: Summit for Clinical Ops Executives
16-17 October 2018, Barcelona, Spain
Building on the
success of its long-running US-based counterpart, Summit for Clinical Trials
Operations Executives Europe (SCOPE Europe) is a two-day event serving clin ops
execs, functional heads, category managers and those responsible for the
planning and management of clinical trials in Europe and the Rest of the World.
More info >> |
|
|
